Drug development In-Depth Focus 2025
This in-depth focus features articles on cell and gene therapy in Europe and enhancing drug delivery with cost-effective solutions.
List view / Grid view
This in-depth focus features articles on cell and gene therapy in Europe and enhancing drug delivery with cost-effective solutions.
Once completed, the Berlin site will also be the new home for one of the company’s Bayer Co. Lab start-up incubators.
EASYGEN is supported by EU funding andindustry partners that include Fresenius, Charles River, Cellix, Pro-Liance and TQ Therapeutics.
Will expand the company’s CAR T-cell therapy footprint and gain access next generation in vivo technology.
The German pharma company’s BioXcellence arm will supply the drug substance for AnGes’ peripheral arterial disease treatment Collategene.
The CDMO’s new site will support its work in cell and gene therapy.
CBER head makes surprise comeback just weeks after his abrupt resignation.